PARAMUS, N.J.--(BUSINESS WIRE)--EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, today announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective.
